160 related articles for article (PubMed ID: 28430398)
21. Impaired bioavailability of famotidine given concurrently with a potent antacid.
Barzaghi N; Gatti G; Crema F; Perucca E
J Clin Pharmacol; 1989 Jul; 29(7):670-2. PubMed ID: 2569486
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers.
Rubbens J; Brouwers J; Tack J; Augustijns P
Eur J Pharm Biopharm; 2016 Dec; 109():122-129. PubMed ID: 27693678
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
Pang J; Dalziel G; Dean B; Ware JA; Salphati L
Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
[TBL] [Abstract][Full Text] [Related]
24. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
25. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
[TBL] [Abstract][Full Text] [Related]
27. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers.
Yin OQ; Bédoucha V; McCulloch T; Zheng C; Zhou W; Hussaini A; Novick S
Cancer Chemother Pharmacol; 2013 Jan; 71(1):219-26. PubMed ID: 23070146
[TBL] [Abstract][Full Text] [Related]
28. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
Kubitza D; Becka M; Zuehlsdorf M; Mueck W
J Clin Pharmacol; 2006 May; 46(5):549-58. PubMed ID: 16638738
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial.
Feldman M
JAMA; 1996 May; 275(18):1428-31. PubMed ID: 8618369
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
32. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.
Musib L; Choo E; Deng Y; Eppler S; Rooney I; Chan IT; Dresser MJ
Mol Pharm; 2013 Nov; 10(11):4046-54. PubMed ID: 24010577
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
Clin Drug Investig; 2014 Oct; 34(10):723-9. PubMed ID: 25145453
[TBL] [Abstract][Full Text] [Related]
34. Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function.
Yu Y; Hoffman J; Plotka A; O'Gorman M; Shi H; Wang D
Cancer Chemother Pharmacol; 2020 Dec; 86(6):701-710. PubMed ID: 33037918
[TBL] [Abstract][Full Text] [Related]
35. Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An
Piscitelli J; Hens B; Tomaszewska I; Wollenberg L; Litwiler K; McAllister M; Reddy M
Mol Pharm; 2023 May; 20(5):2589-2599. PubMed ID: 37037186
[TBL] [Abstract][Full Text] [Related]
36. Effects of antacids and food on absorption of famotidine.
Lin JH; Chremos AN; Kanovsky SM; Schwartz S; Yeh KC; Kann J
Br J Clin Pharmacol; 1987 Oct; 24(4):551-3. PubMed ID: 2891370
[TBL] [Abstract][Full Text] [Related]
37. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
[TBL] [Abstract][Full Text] [Related]
38. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
39. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.
Yasuda S; Higashi S; Murakami M; Tomono Y; Kawaguchi M
Int J Clin Pharmacol Ther; 1999 May; 37(5):249-53. PubMed ID: 10363624
[TBL] [Abstract][Full Text] [Related]
40. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor.
Seiler D; Doser K; Salem I
Arzneimittelforschung; 2011; 61(4):247-51. PubMed ID: 21650084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
